Drug details

Gocovri (amantadine extended release capsules, for oral use)

type of Antiparkinson Agents, Dopamine Agonists, Antivirals, Influenza

Gocovri (amantadine extended release capsules) is an antivirial and anti-Parkinson drug indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• lightheadedness,
• shortness of breath,
• confusion,
• seizure,
• sweating,
• agitation,
• painful or difficult urination,
• swelling in your hands or feet,
• aggression,
• thoughts of self-harm,
• very stiff (rigid) muscles,
• high fever,
• depression,
• hallucinations,
• tremors
• extreme drowsiness,
• falling asleep suddenly even after feeling alert,
• behavior changes,
• fast or uneven heartbeats, and

The following drugs are related to Gocovri, either as a replacement or used together:

• Kynmobi (apomorphine hydrochloride sublingual film)
• Fluorodopa FDOPA (f18 injection)
• Prolixin (fluphenazine)
• Inbrija (levodopa inhalation powder)
• Nourianz (istradefylline tablets)
• Loxitane (loxapine)
• Reglan (metoclopramide)
• Moban (molindone hydrochloride tablets)
• Ongentys (opicapone capsules)